| Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 M Puhr, J Hoefer, G Schäfer, HHH Erb, SJ Oh, H Klocker, I Heidegger, ... The American journal of pathology 181 (6), 2188-2201, 2012 | 272 | 2012 |
| Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines FR Santer, PPS Höschele, SJ Oh, HHH Erb, J Bouchal, IT Cavarretta, ... Molecular cancer therapeutics 10 (9), 1644-1655, 2011 | 239 | 2011 |
| PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21 J Hoefer, G Schäfer, H Klocker, HHH Erb, IG Mills, L Hengst, M Puhr, ... The American journal of pathology 180 (5), 2097-2107, 2012 | 92 | 2012 |
| The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling G Nappo, F Handle, FR Santer, RV McNeill, RI Seed, AT Collins, ... Oncogenesis 6 (5), e342-e342, 2017 | 90 | 2017 |
| Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways SJ Oh, HHH Erb, A Hobisch, FR Santer, Z Culig Endocrine-related cancer 19 (3), 305, 2012 | 70 | 2012 |
| Therapy escape mechanisms in the malignant prostate FR Santer, HHH Erb, RV McNeill Seminars in cancer biology 35, 133-144, 2015 | 69 | 2015 |
| IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 HHH Erb, RV Langlechner, PL Moser, F Handle, T Casneuf, K Verstraeten, ... Endocrine-related cancer 20 (5), 677, 2013 | 62 | 2013 |
| SOCS3 modulates the response to enzalutamide and is regulated by androgen receptor signaling and CpG methylation in prostate cancer cells F Handle, HHH Erb, B Luef, J Hoefer, D Dietrich, W Parson, G Kristiansen, ... Molecular Cancer Research 14 (6), 574-585, 2016 | 45 | 2016 |
| Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers JK Rane, HHH Erb, G Nappo, VM Mann, MS Simms, AT Collins, ... Oncotarget 7 (32), 51965, 2016 | 42 | 2016 |
| The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models F Handle, M Puhr, G Schaefer, N Lorito, J Hoefer, M Gruber, ... Molecular cancer therapeutics 17 (12), 2722-2731, 2018 | 35 | 2018 |
| Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy FR Santer, HHH Erb, SJ Oh, F Handle, GE Feiersinger, B Luef, H Bu, ... Oncotarget 6 (8), 6105, 2015 | 32 | 2015 |
| Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors E Juengel, HHH Erb, A Haferkamp, J Rutz, FKH Chun, RA Blaheta Cancer Letters 435, 121-126, 2018 | 30 | 2018 |
| The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 … A Abazid, B Martin, A Choinowski, RV McNeill, LO Brandenburg, P Ziegler, ... Journal of cellular biochemistry 120 (10), 16711-16722, 2019 | 21 | 2019 |
| Artesunate inhibits the growth behavior of docetaxel-resistant prostate cancer cells O Vakhrusheva, HHH Erb, V Bräunig, SD Markowitsch, P Schupp, ... Frontiers in Oncology 12, 789284, 2022 | 18 | 2022 |
| Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer HHH Erb, J Bodenbender, F Handle, T Diehl, L Donix, I Tsaur, M Gleave, ... PLoS One 15 (8), e0237248, 2020 | 17 | 2020 |
| Metabolic changes during prostate cancer development and progression AMK Beier, M Puhr, MB Stope, C Thomas, HHH Erb Journal of cancer research and clinical oncology 149 (5), 2259-2270, 2023 | 16 | 2023 |
| Systemic triple therapy in metastatic hormone-sensitive prostate cancer (mHSPC): ready for prime time or still to be explored? C Thomas, M Baunacke, HHH Erb, S Füssel, K Erdmann, J Putz, ... Cancers 14 (1), 8, 2021 | 16 | 2021 |
| Impact of STAT proteins in tumor progress and therapy resistance in advanced and metastasized prostate cancer C Ebersbach, AMK Beier, C Thomas, HHH Erb Cancers 13 (19), 4854, 2021 | 15 | 2021 |
| The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy RI Seed, AJ Taurozzi, DJ Wilcock, G Nappo, HHH Erb, ML Read, ... Scientific reports 9 (1), 5120, 2019 | 13 | 2019 |
| Interleukin‐4 induces a CD44high/CD49bhigh PC3 subpopulation with tumor‐initiating characteristics HHH Erb, F Guggenberger, FR Santer, Z Culig Journal of Cellular Biochemistry 119 (5), 4103-4112, 2018 | 12 | 2018 |
Zoran CuligProfessor of Experimental Urology, Medical University of InnsbruckVerified email at i-med.ac.at
